Cat. #151220
Anti-PDECGF [PGF 44C]
Cat. #: 151220
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 1-2 weeks
Target: Platelet-derived endothelial cell growth factor (thymidine phosphorylase); PD-ECGF.
Class: Monoclonal
Application: IHC ; IF ; IP ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Bicknell
Institute: University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-PDECGF [PGF 44C]
- Research fields: Cancer;Immunology;Tissue-specific biology
- Clone: PGF 44C
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 55 kDa (reduced)
- Reactivity: Human
- Host: Mouse
- Application: IHC ; IF ; IP ; WB
- Description: PD-ECGF expression is elevated in breast tumours and is a prognostic factor in colon tumours.
- Immunogen: Full length human protein in E. coli
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
- Recommended controls: HUVEC cell or breast carcinoma
Target Details
- Target: Platelet-derived endothelial cell growth factor (thymidine phosphorylase); PD-ECGF.
- Molecular weight: 55 kDa (reduced)
- Tissue cell line specificity: HUVEC cell or breast carcinoma
- Target background: PD-ECGF expression is elevated in breast tumours and is a prognostic factor in colon tumours.
Applications
- Application: IHC ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Weng et al. 2012. Basic Clin Pharmacol Toxicol. 110(3):298-306. PMID: 21973306.
- Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.
- Ko et al. 2011. J Pharmacol Exp Ther. 338(1):184-94. PMID: 21444628.
- Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
- Giatromanolaki et al. 2003. J Pathol. 200(2):222-8. PMID: 12754744.
- DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer.
- Fox et al. 1997. Ann Oncol. 8(3):271-5. PMID: 9137797.
- Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF.
- Fox et al. 1995. J Pathol. 176(2):183-90. PMID: 7636628.
- Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
- Moghaddam et al. 1995. Proc Natl Acad Sci U S A. 92(4):998-1002. PMID: 7532308.
- Thymidine phosphorylase is angiogenic and promotes tumor growth.
